September 6, 2012 - The U.S. Court of Appeals for the 9th Circuit affirmed the District Courts order granting defendants' motion to dismiss.
November 15, 2010 - The lead plaintiffs filed a notice of appeal.

November 1, 2010 - The court entered a judgement in favor of the defendants and dismissed the case with prejudice.

August 24, 2010 - The court granted defendants' motion to dismiss with leave to amend.

February 16, 2010 - Defendants filed a motion to dismiss.

January 27, 2010 - The lead plaintiff filed another amended consolidated complaint.

December 21, 2009 - The court granted defendants' motion to dismiss with leave to amend.

September 8, 2009 - Defendants filed a motion to dismiss.

July 24, 2009 - The lead plaintiff filed an amended consolidated complaint on behalf of investors who purchased Rigel Pharmaceuticals Inc (NASDAQ: RIGL) common shares between December 13, 2007 and February 3, 2009. The plaintiff alleges that the defendants violated the Securities Act of 1933 and the Securities Exchange Act of 1934 by issuing false and misleading statements between December 13, 2007 and February 3, 2009.

June 9, 2009 - Lead plaintiff and lead counsel were appointed.

April 7, 2009 - Lead plaintiff motion was filed.

March 19, 2009 - Cases were consolidated.

February 6, 2009 - An investor in shares of Rigel Pharmaceuticals Inc (NASDAQ: RIGL) filed a lawsuit in the U.S. District Court for the Northern District of California on behalf of purchasers of Rigel Pharmaceuticals Inc (NASDAQ: RIGL) securities between December 13, 2007 and October 27, 2008, including all persons who acquired the common stock of Rigel Pharmaceuticals Inc pursuant and/or traceable to a false and misleading registration statement and prospectus issued in connection with the Rigel Pharmaceuticals Inc’s February 2008 secondary offering over alleged securities laws violations by Rigel Pharmaceuticals Inc.

According to the complaint the plaintiff alleges that charges Rigel Pharmaceuticals Inc (NASDAQ: RIGL), certain of its officers and directors and the underwriters of the Offering violated the Securities Exchange Act of 1934 and the Securities Act of 1933. The complaint alleges that Rigel Pharmaceuticals Inc was developing a new drug, R788, for the treatment of rheumatoid arthritis. On December 13, 2007, Rigel Pharmaceuticals Inc issued a press release, which was attached as an exhibit to a Form 8-K filed with the SEC, and held a conference call touting the positive summary results of a then-recently-completed clinical trial of R788 in 189 patients in the U.S. and Mexico (the “Study”). In response to the announcement of the summary results of the Study, Rigel Pharmaceuticals Inc’s common stock price more than tripled in one day, from $8 per share to $25.95, so the lawsuit. On January 24, 2008, Rigel Pharmaceuticals Inc filed the Registration Statement for its offering of common stock, which incorporated by reference the December 13, 2007 Form 8-K. On February 6, 2008, Rigel Pharmaceuticals Inc consummated the Offering, selling five million shares of common stock at a price of $27 per share for proceeds of $135 million. Then, on October 27, 2008, Rigel Pharmaceuticals Inc presented the full results of the Study at a meeting of the American College of Rheumatology and on an investor conference call. According to the lawsuit those results contained adverse information omitted from the Rigel Pharmaceuticals Inc’s December 13, 2007 press release and Form 8-K, as well as from the Registration Statement and subsequent presentations. When this adverse information about the Study’s results was finally disclosed, Rigel Pharmaceuticals Inc’s stock price plunged 38% in a single day, from $14.41 to $8.84.